Pipeline

We’re working to identify more unmet medical needs and focus our research where it is needed most. Our growing pipeline includes therapies aimed at providing new solutions in cancer care and rare diseases where no options currently exist, with a goal to help lift the burden of cancer for patients.

Robust R&D Pipeline with significant potential

Near-term and long-term pipeline, securing launches over the coming years.

Notes

The safety and efficacy of the product candidates in the above table have not been established. There is no guarantee that they will receive health authority approval or become commercially available in any country for the uses being investigated.

1. Regulatory: Marketing authorization application upcoming or submitted
2. lnfigratinib is developed globally by Helsinn Healthcare SA in all fields of use except for skeletal dysplasias and except in the following territories: Mainland China, Hong Kong and Macau
3. Approved in U.S., Canada and Australia
4. HM06 is co-developed by Helsinn Healthcare SA and Taiho Pharmaceutical Co. Ltd.
5. GPX4 inhibitor is co-developed by Helsinn Healthcare SA and BridgeBio Pharma, Inc.
6. Chemotherapy-Induced Nausea and Vomiting
7. Approved in multiple territories, including USA and EU
8. Approved in Japan
9. Non-Small Cell Lung Cancer
10. HM01 is developed by Helsinn’s partner, AnaCardio